Intraocular foreign body removal visual outcome may be affected by race, according to a review of IRIS Registry data.
The global burden of vision loss is likely to expand over the next 25 years, with age and socioeconomic index being key factors.
The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback